Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.

Deodhar, Atul   •   Poddubnyy, Denis   •   Pacheco-Tena, Cesar   •   Salvarani, Carlo   •   Lespessailles, Eric   •   Rahman, Proton   •   Jarvinen, Pentti   •   Sanchez-Burson, Juan   •   Gaffney, Karl   •   Lee, Eun Bong   •   Krishnan, Eswar   •   Santisteban, Silvia   •   Li, Xiaoqi   •   Zhao, Fangyi   •   Carlier, Hilde   •   Reveille, John D

published in: Arthritis & rheumatology (Hoboken, N.J.)



endpoint

Ixekizumab has (optional: compared with placebo) proved to be better.
general condition better


basics

diagnosis:
ankylosing spondylitis

localization:
not specified

method:
conservative therapy → injection therapy
conservative therapy → injection therapy
conservative therapy → injection

publication details

10.1002/art.40753
pubmed
30343531
2018
Journal Article
randomized controlled trial
yes
prospective
1+